Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	2.85B -24.5%
Revenue (ttm)	1.02B +42.1%
Net Income	44.99M
EPS	0.36
Shares Out	126.53M
PE Ratio	62.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,942,931
Open	23.31
Previous Close	23.15
Day's Range	22.29 - 24.10
52-Week Range	16.10 - 30.60
Beta	0.24
Analysts	Buy
Price Target	32.16 (+42.55%)
Earnings Date	Feb 27, 2026

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 710
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS
• Website: https://apellis.com

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.

Analyst Summary

According to 20 analysts, the average rating for APLS stock is "Buy." The 12-month stock price target is $32.16, which is an increase of 42.55% from the latest price.

Price Target

$32.16

(42.55% upside)

Analyst Consensus: Buy